SCHEMBL3130256

SCHEMBL3130256

CC(C)(C)OC(=O)N1CC2CN3CCCc4cc(-c5ccccc5)cc(c43)C2C1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 10/20 0.44
GPR119 Q8TDV5 1/20 0.41
RORC P51449 1/20 0.40
CKS1B P61024 2/20 0.39
SKP1 P63208 2/20 0.39
SKP2 Q13309 2/20 0.39
KAT7 O95251 1/20 0.38
KAT8 Q9H7Z6 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
OGFRL1 Q5TC84 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3130259 1.00 USP30 (0.44) USP30GPR119RORCCKS1BSKP1
SCHEMBL3137786 0.86 GPR119 (0.41) USP30GPR119RORCJAK2JAK1
SCHEMBL3137782 0.86 GPR119 (0.41) USP30GPR119RORCJAK2JAK1
SCHEMBL3136405 0.84 USP30 (0.37) USP30GPR119RORCNPC1RAB9A
SCHEMBL3130127 0.84 USP30 (0.37) USP30GPR119RORCNPC1RAB9A
SCHEMBL3136845 0.84 NR1H2 (0.43) USP30GPR119RORCOPRM1OPRD1
SCHEMBL3130120 0.84 USP30 (0.37) USP30GPR119RORCNPC1RAB9A
SCHEMBL3127706 0.84 NR1H2 (0.43) USP30GPR119RORCOPRM1OPRD1
SCHEMBL3138291 0.84 MAPT (0.46) USP30GPR119RORCOPRM1OPRD1
SCHEMBL3133792 0.84 MAPT (0.46) USP30GPR119RORCOPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399445-B9 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2010-07-21 EP disclosed
EP-1399445-B1 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2009-08-05 EP disclosed
US-6777406-B2 SUCH AS PYRIDO(3,2,1-IJ)PYRROLO(3,4-C)QUINOLIN-8-ONE DERI-VATIVES; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-08-17 US disclosed
US-20040092502-A1 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092502-A1 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS HTR1B, HTR2B, HTR1A USP30 4353/4885GPR119 79/4885RORC 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.